Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesBariatric & Obesity ManagementUnitedHealthcare Bariatric Surgery Policy Update C…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedUnitedHealthcarePolicy CS007KY.12

    Bariatric Surgery (for Kentucky Only)

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy CS007KY.12 alerts

    Get alerted when Policy CS007KY.12 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical policy governing bariatric and metabolic surgical procedures for UnitedHealthcare Community Plan members in the state of Kentucky, including coverage rationale, definitions, coding, and documentation requirements.

    Policy Summary
    PayerUnitedHealthcare
    PolicyBariatric Surgery (for Kentucky Only)
    Policy CodePolicy CS007KY.12
    Change TypeMaterial clinical updates and coding additions (08/01/2026)
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionUse InterQual CP Bariatric or Metabolic Surgery criteria to determine medical necessity and document multidisciplinary evaluation and prior conservative therapy when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    Silastic ring vertical gastric bypass was added to the list of unproven and not medically necessary procedures.

    Transoral endoscopic surgery including transoral outlet reduction (TORe) was added to the list of unproven and not medically necessary procedures.

    Stomach aspiration therapy was removed from the list of unproven and not medically necessary procedures.

    Gastrointestinal liners wording was replaced with 'transoral endoscopic surgery including gastrointestinal liners'.

    Intragastric balloon wording was replaced with 'transoral endoscopic surgery including intragastric balloon'.

    Transoral endoscopic surgery language was replaced with 'transoral endoscopic surgery including endoscopic sleeve gastroplasty (includes OverStitch ™ )'.

    Applicable CPT codes were updated to reflect annual edits and code 43889 was added.

    Kentucky-onlygeographic applicability
    InterQualmedical necessity source
    ≥11unproven procedures listed
    43889CPT code added
    6 monthsIGB duration
    1,346By-Band-Sleeve RCT n

    Coverage Criteria and Policy Determinations

    InterQual-based Medical Necessity

    Covered when InterQual CP Bariatric or Metabolic Surgery criteria are met

    InterQual-based coverage: Member meets InterQual CP criteria for Bariatric or Metabolic Surgery (adult) or Bariatric or Metabolic Surgery (Adolescent)see InterQual

    Policy references InterQual for specific clinical criteria and decision logic

    Unproven / Not Medically Necessary Procedures

    Not medically necessary for treating obesity due to insufficient evidence of efficacy

    Unproven bariatric interventions: Bariatric interventions listed in policy (examples): bariatric artery embolization; gastric electrical stimulation with implantable stimulator; laparoscopic greater curvature plication (total gastric vertical plication); mini-gastric bypass/one-anastomosis gastric bypass; silastic ring vertical gastric bypass; single-anastomosis duodenal switch; transoral endoscopic surgery including endoscopic sleeve gastroplasty (includes OverStitch ™ ) and transoral outlet reduction (TORe); vagus nerve blocking (VBLOC ® )
    Policy Summary
    PayerUnitedHealthcare
    PolicyBariatric Surgery (for Kentucky Only)
    Policy CodePolicy CS007KY.12
    Change TypeMaterial clinical updates and coding additions (08/01/2026)
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionUse InterQual CP Bariatric or Metabolic Surgery criteria to determine medical necessity and document multidisciplinary evaluation and prior conservative therapy when applicable.
    SourceLink
    On This Page
    Coverage Criteria and Policy DeterminationsProvider Requirements, Prior Authorization, and DocumentationApplicable Codes, Device Indications, and Key Numeric ThresholdsOperational Notes and Evidence Context for ProvidersDefinitions and Procedure DescriptionsClinical Evidence, Trials, and Supporting InformationPolicy Revision History and Material Changes
    N/A

    Items enumerated in policy chunk 4

    Described surgical and endoscopic bariatric procedures

    Procedures described and clinical considerations

    Procedure descriptions: Documented descriptions of multiple bariatric procedures including: Roux-en-Y gastric bypass (RYGB); laparoscopic adjustable gastric banding; vertical sleeve gastrectomy (VSG); biliopancreatic diversion with duodenal switch (BPD/DS); laparoscopic mini-gastric bypass/one-anastomosis gastric bypass; implantable gastric stimulator; vagus nerve blocking neurostimulation; intragastric balloons (IGBs); laparoscopic greater curvature plication (LGCP); bariatric artery embolization; gastrointestinal liners (e.g., EndoBarrier/DJBL); single-anastomosis duodenal-ileal switch (SADI-S/SADS); endoscopic sleeve gastroplasty (ESG, includes OverStitch); TransPyloric Shuttle device; and revisional bariatric surgery.

    No explicit per-procedure medical necessity decision logic present in these descriptive sections

    SADI-S / SADS clinical evidence

    Evidence summaries and required considerations for SADI-S/SADS:

    SADI-S Evidence Summary: Observational studies (retrospective and prospective cohorts) report substantial mid- to long-term excess weight loss and high rates of comorbidity remission after SADI-S/SADS but are limited by heterogeneity, small samples, and loss to follow-up; late complications include malabsorption and GERD.

    Long-term randomized controlled trial evidence lacking; monitor for malabsorption and GERD after hypoabsorptive procedures

    Comparative outcomes: Comparative cohort studies show similar short- to medium-term weight loss versus BPD/DS and RYGB in small or matched cohorts, with differences in operative time, length of stay, and complication profiles; larger RCTs with longer follow-up are needed.

    Evidence base is primarily observational

    Endoscopic bariatric procedures (ESG, transoral endoscopic)

    Evidence summaries and considerations for endoscopic bariatric procedures (ESG and transoral endoscopic surgery):

    ESG evidence: Randomized and observational studies demonstrate ESG produces greater short-term weight loss than lifestyle modification but less weight loss than laparoscopic sleeve gastrectomy; safety profile includes gastrointestinal symptoms and rare serious adverse events; long-term evidence is limited.

    Comparative trials vs surgical procedures and contemporary pharmacotherapy are limited or absent

    Transoral endoscopic surgery: Current evidence for other transoral endoscopic bariatric procedures is limited and insufficient to fully establish safety and efficacy; additional RCTs and long-term follow-up are warranted.

    Policy may treat these procedures cautiously for coverage pending stronger evidence

    Gastrointestinal liners (EndoBarrier)

    Evidence summaries and considerations for gastrointestinal liners (DJBL/EndoBarrier):

    DJBL evidence: Systematic reviews and meta-analyses report BMI and glycemic improvements while the duodenal-jejunal bypass liner is in situ, but high early removal rates (~19%), substantial incidence of serious adverse events (~17%), and loss of effect after explantation limit long-term utility.

    Device considered investigational pending additional high-quality RCTs and long-term data

    Intragastric balloons

    Evidence summaries and considerations for intragastric balloons (IGBs):

    IGB evidence: Clinical evidence indicates IGBs (endoscopic and ingestible systems) produce short-term, clinically significant weight loss when combined with lifestyle interventions, but are associated with increased adverse events, frequent device intolerance/early removal, and uncertain long-term durability of weight loss after explantation.IGB duration ≤ 6 months per FDA/ASMBS guidance

    Trial inclusion commonly required prior unsuccessful nonsurgical weight loss and adherence to dietary restrictions; programs must ensure follow-up capacity

    Evidence-based coverage considerations (informational)

    Evidence and guideline-derived considerations (no explicit payer coverage logic present in these chunks)

    IGB Evidence Summary: IGBs demonstrate short-term clinically significant weight loss (examples: Orbera, Spatz, Obalon) but have limited long-term durability; safety signals include device intolerance and early removals; professional societies recommend adjunctive lifestyle programs and long-term follow-up.IGB duration ≤ 6 months

    ASGE PIVI thresholds met for some devices (Orbera) although long-term benefit remains uncertain

    Device and therapy considerations: Feasibility and small trials for devices (e.g., TransPyloric Shuttle) show weight loss and quality-of-life improvements but are limited by small samples and short follow-up; vagus nerve blocking and other implantable stimulators have mixed RCT results and require more evidence.

    Coverage determinations rely on overall policy clinical criteria and InterQual where applicable

    Guideline Recommendations: Professional societies (AGA, ASGE, ASMBS, AACE) advise that EBTs and IGBs be used as adjuncts to supervised lifestyle programs, with prophylactic measures (eg, PPI) and requirement for programs to provide long-term follow-up and maintenance strategies after device removal.

    Informational guidance to support prior authorization and documentation expectations

    Indications for MBS per major societies

    Society guideline indications and selection considerations for bariatric/metabolic surgery

    General candidate criteria: Patient selection should consider BMI thresholds (eg, BMI ≥40 kg/m2; BMI ≥35 kg/m2 with significant comorbidities; consideration of BMI 30–34.9 kg/m2 for select patients with metabolic disease), presence and severity of comorbidities, individualized goals, local expertise, and patient preferencesee BMI thresholds in guideline statements

    Include ethnicity-based BMI adjustments and consideration for adolescents

    Endoscopic therapies (IGB) guidance

    Endoscopic bariatric therapies (EBTs) and intragastric balloons

    EBT evidence and requirements: FDA-approved intragastric balloons (eg, Orbera) and other EBTs that meet professional-society performance thresholds should be considered adjuncts to supervised lifestyle programs; IGBs are temporary (maximum 6 months) and require programmatic follow-up and maintenance planningIGB duration ≤ 6 months

    ASGE PIVI thresholds and AGA recommendations inform appropriate use and follow-up

    Revisional bariatric surgery

    Revisional bariatric surgery considerations

    Reoperative selection and risks: Reoperative procedures should be based on identified cause (insufficient weight loss, weight regain, persistent comorbidity, or complications) and be procedure-specific; candidacy requires a thorough multidisciplinary assessment and documentation; reoperations carry higher morbidity and require careful selectionconsider limb lengths and nutritional monitoring after distalization

    Surgeon experience, anatomy, prior procedure, and patient factors should guide procedure selection

    Revisional Bariatric Surgery — General coverage criteria

    Covered when patient evaluation and procedure selection meet multidisciplinary assessment and indication criteria

    Revisional surgery candidacy: Patient has indication for additional surgical therapy (eg, insufficient weight loss, persistent comorbidity, weight regain, or complication warranting corrective/conversion operation); AND a thorough multidisciplinary evaluation has been performed to determine cause and to select the appropriate revisional procedure based on prior operation, anatomy, weight/comorbidities, and surgeon experience

    Reoperative procedures carry higher risk and require documentation of multidisciplinary assessment

    Distalization-specific criteria

    Additional requirement for distalization procedures

    Distalization risk mitigation: When performing distalization of RYGB as a revisional procedure, document plans for aggressive vitamin supplementation and regular nutrition monitoring due to risk of severe macro- and micronutrient deficiencies, particularly when the common channel (CC) is < 200 cm or the total alimentary limb length (TALL) is < 400 cmCC < 200 cm; TALL < 400 cm

    Nutritional monitoring and supplementation plans must be documented prior to surgery

    Pediatric surgery criteria

    Pediatric metabolic/bariatric surgery considerations

    Pediatric eligibility (per society guidance): For patients under 18 years, candidacy should be determined by a multidisciplinary team and typically requires Tanner stage 4–5 with final or near-final height (or age ≥12 years per some guidance), meeting BMI/comorbidity thresholds (eg, Class II: ≥120% of 95th percentile or BMI 35–39.9; Class III: ≥140% of 95th percentile or BMI ≥40 kg/m2) and significant comorbidities; psychosocial and family assessment and access to an experienced pediatric bariatric center with long-term follow-up are requiredAge and BMI thresholds per cited society statements

    Exclude pregnant or breastfeeding adolescents and patients with unresolved substance use, eating disorders, or untreated psychiatric illness

    Device-specific FDA indication criteria (informational for coverage determination)

    Covered when ALL FDA-labeled selection criteria are met for the specific device (informational; coverage decisions rely on policy-wide clinical criteria elsewhere).

    LAP-BAND (FDA labeling): Patient is an adult with BMI ≥ 40 kg/m2 OR BMI ≥ 35 kg/m2 with one or more severe comorbid conditions OR 100 lb or more over estimated ideal weight, and has experienced failure of supervised conservative weight-reduction alternatives (diet, exercise, behavior modification)see FDA labeling

    Per LAP-BAND PMA and labeling; adjustable gastric bands contraindicated in patients <18 years

    LAP-BAND expanded indication (2011)

    Additional FDA-labeled selection criteria after 2011 approval.

    2011 LAP-BAND expansion: Per 2011 FDA approval expansion: patient eligibility includes BMI ≥ 40 kg/m2 OR BMI ≥ 30 kg/m2 with one or more obesity-related comorbid conditionssee FDA labeling

    Informational; conservative therapy failure per labeling

    TransPyloric Shuttle (PMA 2019)

    FDA premarket approval indication.

    TransPyloric Shuttle: Adult patient with BMI 35.0–40.0 kg/m2 OR BMI 30.0–34.9 kg/m2 with one or more obesity-related comorbid conditions; device to be used in conjunction with diet and behavior modification; approved for up to 12 months of therapy per PMAsee PMA labeling

    Informational—document device-specific selection criteria when requesting authorization

    EndoBarrier

    Investigational status.

    EndoBarrier: The EndoBarrier duodenal-jejunal bypass liner has investigational device exemption (IDE) status and is not FDA-approved for marketing; use is considered investigational pending approvals and additional evidenceIDE status

    Device remains investigational per FDA IDE (Aug 2018)

    The policy explicitly states that bariatric surgery performed as the primary treatment for any condition other than obesity is unproven and not medically necessary. This listing is part of the policy’s enumerated unproven / not medically necessary procedures and therefore is excluded from favorable coverage absent evidence supporting that indication.

    Gastrointestinal liners such as the EndoBarrier™ are described in the policy as not approved by the U.S. Food and Drug Administration for use in the United States and are therefore limited by federal law to investigational use only. The policy groups gastrointestinal liners under transoral endoscopic approaches and treats EndoBarrier as investigational pending additional clinical evidence and regulatory approval.

    The policy concludes that bariatric artery embolization remains investigational and unproven because available human studies are small, methodologically limited, use variable techniques, and lack long‑term safety and efficacy data. As such, the procedure is presented as not established and treated as an investigational/non‑covered approach until larger, controlled datasets demonstrate benefit and acceptable risk.

    Implantable gastric electrical stimulation is described as having insufficient high‑quality evidence regarding magnitude and durability of effect and an unclear risk profile. The policy therefore characterizes gastric electrical stimulation as investigational, reflecting an implied exclusion from standard coverage pending more robust randomized data and long‑term outcomes.

    The policy notes that laparoscopic greater curvature plication (LGCP) provides inferior and less durable weight loss compared with established procedures and carries notable revision and complication rates. Given these comparative limitations and the need for additional high‑quality RCTs, LGCP is listed among unproven interventions and is suggested to be excluded from standard coverage.

    Several procedures are identified as having insufficient evidence, higher complication rates, or limited long‑term outcomes. These include LGCP (high revision and weight‑regain concerns), OAGB/MGB (higher rates of de novo GERD and marginal ulcers in pooled analyses), silastic ring vertical gastric bypass (SRVGB) (device‑specific late complications and lack of standardization), and SADI‑S/SADS (promising short‑ to mid‑term weight loss but limited long‑term safety data and risk of malabsorption). The policy treats these techniques cautiously and may restrict or consider them not medically necessary pending stronger evidence.

    The policy highlights procedures and devices with mixed or insufficient evidence—examples include transoral endoscopic surgery (including endoscopic sleeve gastroplasty and TORe), certain ingestible intragastric balloons, and duodenal‑jejunal bypass liners (DJBL/EndoBarrier). These interventions are described as requiring additional randomized trials and long‑term outcome data before they can be considered established therapy; until such evidence is available, they are presented as investigational or limited‑evidence options.

    The clinical evidence summaries do not list explicit blanket exclusions for some devices but emphasize that available studies show inconclusive long‑term benefit, frequently high loss to follow‑up, and—for some products—lack of regulatory approval. The policy therefore treats such technologies as unproven or investigational and notes that long‑term effectiveness is uncertain unless paired with sustained adjunctive treatments.

    Although no explicit exclusion language appears in this excerpt for all intragastric balloon contexts, the policy references ASMBS guidance that emphasizes adherence to contraindications, timely device removal, and careful patient selection to mitigate safety risks. That guidance informs the policy’s cautious stance toward certain balloon uses.

    Pediatric considerations are stated clearly: bariatric surgery should not be performed in preadolescent children, and it should be avoided in pregnant or breastfeeding adolescents and those planning pregnancy within two years. Pediatric eligibility requires multidisciplinary assessment and adherence to society guidance on maturity and psychosocial readiness.

    The policy lists several relative contraindications that may preclude operative candidacy or require careful evaluation, including severe heart failure, unstable coronary artery disease, end‑stage lung disease, active cancer diagnosis/treatment, cirrhosis with portal hypertension, uncontrolled substance use, and severely impaired intellectual capacity. These conditions warrant individualized risk‑benefit assessment prior to considering bariatric procedures.

    Per FDA labeling cited in the policy, adjustable gastric bands are contraindicated in patients younger than 18 years of age. This device‑specific contraindication is noted as a potential basis for noncoverage when applied outside the labeled population.

    The policy enumerates specific procedures designated as unproven and not medically necessary; the 08/01/2026 revision explicitly added silastic ring vertical gastric bypass and clarified transoral endoscopic groupings (including TORe). These named interventions are listed as not medically necessary due to insufficient evidence supporting safety and long‑term efficacy.

    Interventions listed in the policy’s unproven list—including endovascular, implantable stimulation, various endoscopic and surgical variants, and device therapies—are characterized as not medically necessary for treating obesity when evidence is insufficient. Transoral endoscopic procedures and gastrointestinal liners (e.g., EndoBarrier) are specifically referenced as investigational or not approved, supporting their not‑medically‑necessary designation.

    Transoral endoscopic approaches (including endoscopic sleeve gastroplasty, TORe, and other natural‑orifice techniques) and certain gastrointestinal liners are presented as investigational or investigational options in the policy; the EndoBarrier device is specifically noted as not FDA‑approved and limited to investigational use in the U.S.

    Because the policy finds that bariatric artery embolization evidence is limited, heterogeneous, and of small size with unclear long‑term outcomes and safety, it is described as unproven; this supports an investigational or not‑medically‑necessary classification until higher‑quality controlled data become available.

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Use InterQual criteria to establish medical necessity

    Medical necessity determinations for bariatric and metabolic surgical procedures rely on the referenced InterQual CP criteria for Bariatric or Metabolic Surgery (adult) and Bariatric or Metabolic Surgery (Adolescent).

    Prior Authorization

    Prior authorization: document multidisciplinary assessment for revisional surgery

    When requesting authorization for revisional bariatric surgery, include documentation that a thorough multidisciplinary assessment was performed and that the revision is indicated (for example, due to anatomical causes, complications, or device issues) rather than solely behavioral factors.

    • Document multidisciplinary evaluation findings and rationale for revision
    • Describe prior procedure(s), complications, and anatomical findings
    • Show consideration of nonoperative management and MBSAQIP center accreditation where applicable
    Note

    No specific CPT/HCPCS prior-authorization list in this section

    This policy excerpt provides clinical evidence and guidance but does not list specific CPT or HCPCS codes that by itself mandate prior authorization; applicable authorization requirements are determined by InterQual and the payer’s administrative rules.

    Prior Authorization

    Prior authorization advised for less-proven procedures

    For procedures with limited, mixed, or insufficient long-term evidence (for example LGCP, OAGB/MGB, SRVGB, and some SADI-S/SADS reports), prior authorization may be required and should include supporting clinical evidence and justification.

    • Provide clinical rationale and available outcome data when seeking coverage
    • Include surgeon experience and follow-up plans when evidence is limited
    Prior Authorization

    Align prior-authorization info with IGB trial inclusion criteria

    When intragastric balloon (IGB) or similar device use is proposed based on trial populations, prior authorization should reflect trial-like inclusion elements: adult age, BMI ≥ 30 kg/m2, prior unsuccessful nonsurgical weight-loss attempts, and willingness to adhere to required dietary restrictions and follow-up.

    • Confirm patient age and BMI meet study-referenced thresholds
    • Document history of failed conservative weight-loss efforts
    • Document patient agreement to required dietary program and follow-up schedule
    Prior Authorization

    Authorization must confirm trial-like eligibility elements

    Prior authorization review should verify that the patient meets the study-type eligibility elements commonly used in IGB and device trials (for example BMI thresholds and documented prior failure of conservative therapy) before approving device-based interventions.

    • Verify BMI and comorbidity criteria documented in the record
    • Confirm documented prior conservative therapy attempts and their duration
    • Include planned multidisciplinary follow-up in the authorization request
    Billing Rule

    IGB: limit duration and ensure removal/follow-up capability

    Intragastric balloons are temporary devices; follow FDA and ASMBS guidance limiting implantation to a maximum of 6 months and ensure programs can provide timely removal and appropriate follow-up to mitigate device-related complications.

    • Document plan for device removal within the 6-month maximum
    • Document ability to provide nutrition follow-up and complication management
    Prior Authorization

    Prior authorization must document indications and prior-procedure details for revisional surgery

    Prior authorization for revisional surgery should include evidence of multidisciplinary evaluation, the specific indication for revision (insufficient weight loss, persistent comorbidity, or complication), and details of the prior procedure and outcomes.

    • Provide prior operative reports and documentation of prior outcomes
    • Describe the multidisciplinary team's assessment and recommended plan
    • Detail anticipated benefits and the management plan for increased reoperative risks
    Documentation Required

    Document FDA-indicated selection criteria for device requests

    When seeking authorization for device-based therapies, document that the patient meets FDA-labeled selection criteria for the specific device (for example LAP-BAND and TransPyloric Shuttle BMI and comorbidity thresholds) as applicable.

    • Include device name and FDA-indicated BMI/comorbidity criteria in the record
    • Document prior failure of supervised conservative therapies when required by labeling
    Billing Rule

    Authorization requests: follow InterQual and include updated CPT codes

    Prior authorization and utilization review may be required per InterQual and UnitedHealthcare medical policy criteria; the policy’s applicable CPT code list was updated and includes added code 43889.

    • Use InterQual decision support for clinical criteria during authorization
    • When submitting, include applicable CPT codes (note 43889 added in update)
    Step Therapy

    Confirm first-line conservative treatments attempted

    First-line obesity treatments (dietary therapy, physical activity, behavior modification, and medication management) are expected to have been attempted prior to consideration of procedural interventions.

    Documentation Required

    Record failed conservative therapy prior to procedural consideration

    Document attempts at conservative obesity treatment—diet, physical activity, behavior modification, and medication management—before proceeding to invasive procedures when indicated by societal guidance.

    • Record duration and type of supervised programs or pharmacotherapy trials
    • Include documentation of outcomes and adherence
    Note

    No explicit step-therapy requirements specified here

    No explicit step-therapy program requiring sequential trials is described in this excerpt; device and interventional approaches are assessed against evidence and may be considered investigational or unproven.

    Step Therapy

    Prefer established procedures before less-proven alternatives

    Providers and reviewers should favor established procedures (e.g., LSG, RYGB) over less-proven alternatives when comparative data show inferior or less durable outcomes or higher complication rates for the alternative (for example LGCP vs LSG).

    • Provide comparative outcome data if proposing less-proven procedures
    • Explain why standard procedures are not appropriate in the individual case
    Step Therapy

    Require documented conservative management before ESG

    Endoscopic sleeve gastroplasty (ESG) is typically considered only after documentation of unsuccessful conservative management; authorization should include evidence of prior lifestyle interventions.

    • Document prior supervised diet/exercise programs and their results
    • Include plan for concurrent multidisciplinary follow-up after ESG
    Step Therapy

    Follow guideline-based sequencing versus device-first approaches

    Consider metabolic surgery or intensification of medical therapy for diabetes per ADA guidance (including BMI and comorbidity thresholds) before device-only interventions when clinically appropriate; document guideline-based sequencing in the record.

    • Document consideration of ADA-recommended options and rationale for chosen therapy
    • Include specialist weight-management assessment when indicated
    Documentation Required

    Document multidisciplinary care prior to device therapy

    Before device therapy, include evidence of a multidisciplinary approach—nutrition, behavioral health, and surgical assessment—and plans for supervised lifestyle intervention alongside the device.

    • Document team members involved and their recommendations
    • Provide plan for post-procedure lifestyle support and monitoring
    Note
    Note
    Note
    Documentation Required

    Maintain complete, legible medical-record documentation for reviews

    Ensure medical records contain legible documentation that fully supports medical necessity, including relevant history, physical exam, diagnostic test results, and prior weight-loss attempts; records must be available upon request.

    • Include past weight history, prior interventions, and objective measures (BMI, labs)
    • Maintain legible, retrievable records for utilization review
    Documentation Required

    Adolescent and revisional-case documentation requirements

    For adolescents, document use of gender-specific CDC growth and BMI charts to support assessments of development and maturation; for revisional cases, include prior procedure details and outcomes in the record.

    • Attach CDC growth/BMI charts and note Tanner stage or maturity where applicable
    • Include prior operative reports and reason for considering revision
    Note
    Documentation Required

    Supportive documentation required for SADI-S/SADS submissions

    When submitting requests for SADI-S/SADS or similar hypoabsorptive procedures, include documentation of indication (BMI, comorbidities), prior procedures if revisional, and surgical technique standardization and follow-up plans.

    • Provide BMI and comorbidity data, prior operative details, and planned nutrition monitoring
    • Document surgeon experience and technique standardization where possible
    Documentation Required

    Document prior failed nonsurgical weight loss and planned adherence for IGBs

    Trials of intragastric balloons required documented prior failure of nonsurgical weight-loss attempts and adherence to dietary restrictions with close follow-up; authorization for IGBs should include similar documentation.

    • Document prior nonsurgical weight-loss attempts and outcomes
    • Confirm patient willingness to adhere to dietary restrictions and scheduled follow-up
    Documentation Required

    Document prior unsuccessful nonsurgical methods and follow-up agreement

    Providers should document prior unsuccessful nonsurgical weight-loss methods and patient willingness to comply with required dietary restrictions and follow-up, as many device trials required these elements for inclusion.

    • List prior programs, duration, and results
    • Include signed patient agreement to follow-up regimen when available
    Documentation Required

    Document comprehensive preoperative evaluation

    Perform and document a comprehensive preoperative evaluation including an obesity-focused history, weight history, comorbidities, prior weight-loss attempts, and results of pertinent laboratory and diagnostic testing.

    • Record weight trajectory, comorbidity status, and relevant labs
    • Include psychosocial and behavioral health assessments as appropriate
    Documentation Required

    Expect multidisciplinary and pediatric-specific documentation

    Thorough multidisciplinary evaluation documentation is expected for patients considered for reoperative or primary metabolic/bariatric surgery; for pediatric candidates, document family psychosocial assessment, puberty status, and evidence of prior lifestyle modification.

    • Include team assessments (nutrition, behavioral health, surgery) and family support evaluation for adolescents
    • Document Tanner stage or near-final height and access to pediatric bariatric expertise
    Documentation Required

    Include device identification and FDA approval details in documentation

    Identify devices in the record using FDA product codes or approval documents (for example OverStitch, TransPyloric Shuttle) when applicable to support device-specific claims.

    • List device model and reference FDA approval or product code when applicable
    Denial Risk

    Risk of denial if documentation is insufficient or unavailable

    Medical records that do not fully support medical necessity or are unavailable upon request may trigger denial; ensure records comprehensively justify the requested service.

    • Provide legible records with relevant history, exam findings, and diagnostic results
    • Be prepared to supply records promptly for utilization review
    Note
    Denial Risk

    Denial risk: inadequate documentation for revisional surgery

    Failure to document a thorough multidisciplinary assessment and explicit consideration of risks and benefits for revisional bariatric surgery may result in denial of coverage.

    • Document why revision is anatomically or medically indicated versus behavioral
    • Provide evidence of MBSAQIP accreditation or equivalent program resources when available
    Note
    Denial Risk

    Denial risk: insufficient evidence or higher complication profiles

    Procedures with limited long-term evidence or evidence of higher complication rates (for example OAGB with higher de novo GERD, SRVGB device-specific late risks, or procedures lacking long-term durability) may be denied or require additional justification.

    • Provide long-term outcome data and risk mitigation plans when available
    • Explain rationale for choosing a higher-risk procedure over established options
    Denial Risk

    Denial risk: limited evidence for some endoscopic procedures

    Procedures lacking adequate evidence of safety and efficacy (for example transoral endoscopic surgery and some GI liners) have uncertain benefit and may be at higher risk of denial absent strong supporting documentation.

    • Include robust clinical data or trial enrollment information if proposing these procedures
    • Indicate participation in research protocols or specialized governance when applicable
    Denial Risk

    Denial risk: evidence limitations for long-term device benefit

    Lack of long-term safety or durability data and high loss-to-follow-up rates in studies of devices intended for durable benefit (such as some IGBs and liners) may support a medical necessity denial unless plans for long-term adjunctive treatment and follow-up are documented.

    • Document planned long-term treatment strategy (pharmacotherapy, repeat interventions, or surgery) after device removal
    • Provide follow-up plan to address expected weight regain risks
    Denial Risk

    Do not deny solely for lack of preoperative weight loss program

    There is no high-level evidence to mandate preoperative supervised weight loss; therefore, denial based solely on absence of documented preoperative weight loss programs is not supported by ASMBS guidance and may risk inappropriate denial.

    Documentation Required

    Document selection and nutrition plans for distalization/reoperation

    Due to higher morbidity with reoperative bariatric surgery and the nutritional risks after distalization when common channel length is < 200 cm or total alimentary limb length is < 400 cm, document careful patient selection and plans for aggressive nutrition monitoring and supplementation.

    • Specify anticipated limb lengths and monitoring/supplementation protocols when distalization is planned
    • Document informed consent discussing malnutrition risks
    Denial Risk

    Contraindication: adjustable gastric bands in patients <18 years

    Adjustable gastric bands are contraindicated in patients younger than 18 years of age; use outside FDA indications may risk noncoverage or denial.

    • Do not request banding procedures for patients under 18 without explicit rationale and applicable exceptions
    • Document FDA-indicated criteria when proposing banding in adults
    Note

    Applicable Codes, Device Indications, and Key Numeric Thresholds

    Applicable CPT CodesCPT
    0813TEsophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon.
    43290Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon.
    43291Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s).
    43644Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less).
    43645Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption.
    43647Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
    43648Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
    43659Unlisted laparoscopy procedure, stomach.
    43770Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components).
    43771Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only.
    1–10 of 31
    1/4
    Covered CPT Codesmixed
    No codes listed
    FDA product codes (surgical staplers)mixed
    GDWProduct code for certain surgical stapling devices (as listed)
    GAGProduct code for certain surgical stapling devices (as listed)
    Applicable CPT Codes (updated)CPT
    43889CPT code added (description as per annual edits)
    Standard BMI categories
    UnderweightBMI < 18.5 kg/m²
    Normal weightBMI 18.5–24.9 kg/m²
    OverweightBMI 25–29.9 kg/m²
    Obesity Class IBMI 30–34.9 kg/m²
    Obesity Class IIBMI 35–39.9 kg/m²
    Obesity Class IIIBMI ≥ 40 kg/m²
    Intragastric balloon duration — 6 months
    Standard duration6 months (maximum placement period for FDA‑approved intragastric balloons)
    PurposeTemporary, adjunctive to diet, exercise, and behavioral counseling
    Follow-up requirementPrograms should ensure ability to provide long‑term follow‑up to avoid device‑related complications
    BMI range in Xie et al. Apnea study
    Study median BMIMedian BMI 49 kg/m²
    RangeRange 36–69 kg/m²
    Population size167 participants (Xie et al., 2016)
    ASGE PIVI effectiveness threshold
    ASGE PIVI effectiveness threshold≥ 5% total body weight loss (TWL) at prespecified timepoints
    Orbera performanceOrbera IGB pooled TWL/TWL outcomes exceeded the 5% PIVI threshold in meta-analysis
    Safety threshold referencedPooled serious adverse event (SAE) rates compared against PIVI safety thresholds
    BMI thresholds — examples from society guidance
    Severe obesity / primary thresholdBMI ≥ 40 kg/m²
    Class II threshold with comorbidityBMI ≥ 35 kg/m² with one or more severe obesity‑related comorbidities (eg, T2D, OSA)
    Select patients with metabolic diseaseBMI 30–34.9 kg/m² for select patients with T2D or metabolic disease when inadequate control despite medical therapy
    Common channel concerns in distalization
    High‑risk CC lengthCommon channel (CC) < 200 cm associated with high risk of severe macro‑ and micronutrient deficiencies after distalization
    Clinical implicationAggressive vitamin supplementation and regular nutrition monitoring should be planned and documented when CC < 200 cm
    Evidence sourceASMBS literature review and revision task force summaries
    Common channel length — clinical risk
    Risk thresholdCommon channel length < 200 cm associated with risk of severe macro‑ and micronutrient deficiencies
    Monitoring requirementDocumented plan for aggressive supplementation and nutrition monitoring is required for distalization procedures
    ContextFindings based on ASMBS review of RYGB limb length outcomes
    Total alimentary limb length (TALL)
    TALL risk thresholdTotal alimentary limb length (TALL) < 400 cm associated with increased risk of nutritional deficiencies
    DefinitionTALL = alimentary limb length (AL) + common channel (CC)
    Clinical actionPlan and document aggressive supplementation and long‑term nutrition follow‑up when TALL < 400 cm
    Device BMI indications (labeling highlights)
    Orbera (Intragastric Balloon)Indicated for adults with BMI ≥ 30 kg/m² and ≤ 40 kg/m² (FDA labeling); maximum placement 6 months
    TransPyloric ShuttlePMA indication: BMI 35.0–40.0 kg/m² OR BMI 30.0–34.9 kg/m² with one or more obesity‑related comorbid conditions; use with diet/behavior modification
    LAP‑BAND (adjustable gastric band)FDA labeling: BMI ≥ 40 kg/m² OR BMI ≥ 35 kg/m² with one or more severe comorbid conditions; expanded 2011 labeling includes BMI ≥ 30 kg/m² with comorbidity
    BMI thresholds — LAP‑BAND and TransPyloric Shuttle labeling
    LAP‑BAND labeling specificsOriginal FDA PMA: BMI ≥ 40 kg/m² or BMI ≥ 35 kg/m² with one or more severe comorbid conditions (or ≥100 lb over ideal); 2011 expansion included BMI ≥ 30 kg/m² with comorbidity
    TransPyloric Shuttle labelingPMA: BMI 35.0–40.0 kg/m² or BMI 30.0–34.9 kg/m² with one or more obesity‑related comorbid conditions; used with diet/behavior modification

    Operational Notes and Evidence Context for Providers

    The policy cites an ECRI assessment indicating that the Orbera intragastric balloon yields short‑term weight loss but that most individuals regain much of the lost weight within 6–12 months after removal unless followed by effective long‑term treatments. The absence of durable long‑term benefit is highlighted as a limitation for establishing routine coverage.

    The policy references ASMBS guidance noting that there is no randomized controlled trial, large prospective study, or meta‑analysis to support mandated preoperative supervised weight loss. Therefore, denying coverage solely because a patient did not complete a preoperative supervised weight loss program is not supported by that society guidance.

    The policy positions endoscopic sleeve gastroplasty (ESG) as a therapy that has demonstrated greater short‑term weight loss than lifestyle modification but less weight loss than laparoscopic sleeve gastrectomy. Consistent with evidence and guideline recommendations, ESG is framed to follow documentation of failed conservative measures and be delivered within a program capable of long‑term follow‑up.

    Society guidance cited in the policy (for example ADA recommendations) informs sequencing decisions: consider metabolic surgery or intensification of medical therapy for diabetes per ADA before device‑based interventions when appropriate. Device therapies should be considered in the context of guideline‑recommended care and individualized patient factors.

    Definitions and Procedure Descriptions

    Body Mass Index (BMI) — definition and categories
    BMI definitionWeight (kg) divided by height (m) squared
    UnderweightBMI < 18.5 kg/m²
    Normal weightBMI 18.5–24.9 kg/m²
    OverweightBMI 25–29.9 kg/m²
    Obesity Class IBMI 30–34.9 kg/m²
    Obesity Class IIBMI 35–39.9 kg/m²
    Obesity Class IIIBMI ≥ 40 kg/m²
    Adolescent obesity classification
    Class II severe obesity (adolescents)≥ 120% of the 95th percentile for age/sex OR absolute BMI 35–39.9 kg/m² (whichever is lower)
    Class III severe obesity (adolescents)≥ 140% of the 95th percentile for age/sex OR absolute BMI ≥ 40 kg/m² (whichever is lower)
    Assessment toolUse gender‑specific CDC growth and BMI charts for adolescents
    Obstructive Sleep Apnea (OSA) severity
    Mild OSAAHI or RDI ≥ 5 and < 15 events/hour
    Moderate OSAAHI or RDI ≥ 15 and ≤ 30 events/hour
    Severe OSAAHI or RDI > 30 events/hour
    Revisional Bariatric Surgery — types
    ConversionA second bariatric procedure that changes the approach to a different type of bariatric operation
    CorrectiveA procedure that corrects or modifies anatomy of a previous bariatric procedure to achieve the original desired outcome or correct a complication
    ReversalA procedure that restores original anatomy
    Restrictive vs Malabsorptive procedures
    Restrictive proceduresReduce stomach volume to limit intake (eg, sleeve gastrectomy, gastric banding)
    Malabsorptive proceduresLimit intestinal absorption of nutrients (eg, biliopancreatic diversion with duodenal switch)
    Combination approachesSome procedures combine restrictive and malabsorptive mechanisms
    Roux‑en‑Y gastric bypass (RYGB)
    Procedure descriptionRYGB creates a small stomach pouch attached directly to the small intestine, bypassing most of the stomach and duodenum
    MechanismRestrictive and malabsorptive components depending on limb lengths
    Evidence contextCompared in RCTs for weight loss and quality‑of‑life outcomes (eg, By‑Band‑Sleeve trial)
    Vertical sleeve gastrectomy (VSG)
    Procedure descriptionVertical sleeve gastrectomy removes ~60–75% of the stomach to create a narrow gastric tube and reduce ghrelin production
    MechanismPrimarily restrictive; not purely malabsorptive; lifetime supplementation not universally required
    Comparative outcomesLSG compared with ESG and RYGB in trials with differing weight‑loss durability
    RYGB — trial comparison context
    ContextRYGB evaluated in randomized trials such as the By‑Band‑Sleeve Collaborative Group RCT comparing RYGB, adjustable gastric banding, and sleeve gastrectomy
    OutcomesMean % total weight loss at 3 years reported (eg, RYGB −26.8%)
    RelevanceUsed as benchmark in comparative effectiveness studies
    Endoscopic Sleeve Gastroplasty (ESG)
    DefinitionEndoscopic Sleeve Gastroplasty (ESG) is a minimally invasive endoscopic suturing procedure (eg, OverStitch) that reduces gastric volume
    DevicesApollo ESG System / OverStitch (510(k) cleared for endoscopic suturing)
    EvidenceRCTs and observational studies show greater short‑term weight loss than lifestyle modification but less than LSG; long‑term data limited
    Duodenal‑jejunal bypass liner (DJBL / EndoBarrier)
    DefinitionDuodenal‑jejunal bypass liner (DJBL/EndoBarrier) is a temporary endoscopically placed gastrointestinal liner that bypasses proximal small intestine
    Short‑term effectsPooled BMI and glycemic improvements while device in situ; pooled TWL ~13.1% at 12 months in meta‑analysis
    Safety concernsHigh early removal (~19%) and SAE incidence (~17%) limit long‑term utility
    Intragastric Balloons (IGB)
    DefinitionIntragastric balloons (IGBs) are temporary space‑occupying devices inserted endoscopically or ingested to induce early satiety
    EfficacyProduce short‑term clinically significant weight loss (eg, TBWL up to ~15% at ~32 weeks in Spatz trial)
    Safety and durabilityAssociated with increased adverse events, common device intolerance/early removal, and frequent weight regain after removal; FDA‑approved IGBs have max 6‑month placement
    TBWL / EWL definitions
    TBWL definitionTotal body weight loss = percent of total body weight lost
    EWL definitionExcess weight loss = percent of excess weight lost compared with ideal weight
    Clinical thresholdsTrials commonly report TBWL and EWL at fixed timepoints (eg, 24–32 weeks)
    PIVI thresholds (ASGE)
    PIVI thresholds overviewASGE PIVI sets performance thresholds (eg, minimum % TBWL and acceptable SAE rates) for adoption of endoscopic bariatric therapies
    ApplicationOrbera and certain transoral outlet reduction procedures have met PIVI thresholds in meta‑analyses cited
    RoleGuides inclusion of EBTs as adjuncts to lifestyle programs when thresholds are met
    Metabolic and Bariatric Surgery (MBS)
    DefinitionMetabolic and Bariatric Surgery (MBS) refers to surgical procedures intended to produce weight loss and metabolic improvement
    IndicationsRecommended for patients meeting BMI thresholds and metabolic disease criteria per society guidelines
    Long‑term managementSevere obesity is a chronic disease requiring long‑term follow‑up after MBS
    Intragastric Balloon (IGB) — definition and FDA time limit
    Definition and FDA time limitIGB is an endoscopic, temporary device FDA‑approved for up to 6 months and used as adjunct to lifestyle therapy
    Adjunctive useIntended to be used with long‑term supervised diet and behavior modification to increase likelihood of durable weight loss
    Safety noteAbility to provide appropriate follow‑up is essential to enhance safety and avoid complications
    Corrective operation — definition
    Corrective operationAn operation addressing complications or incomplete treatment effect of prior bariatric operation without changing initial operation
    ImplicationCorrective operations compose the majority of reoperations (eg, 69.5% corrective vs 30.5% conversions in task force review)
    DocumentationMultidisciplinary evaluation and clear indication documentation expected for corrective procedures
    Conversion — definition
    ConversionAn operation that changes the index bariatric operation to a different type of bariatric operation
    Outcome noteMean % EBWL after conversion reported ~39.3% (task force review), lower than primary operation but clinically significant
    SelectionProcedure selection should be individualized based on anatomy, prior procedure, and surgeon experience
    Severely obese (per LAP‑BAND labeling)
    Severely obese (LAP‑BAND labeling)BMI ≥ 40 kg/m² OR BMI ≥ 35 kg/m² with one or more severe comorbid conditions OR ≥100 lb over estimated ideal weight
    Original requirementUse only after failure of supervised conservative weight‑reduction alternatives
    Age contraindicationAdjustable gastric bands are contraindicated in patients younger than 18 years
    TransPyloric Shuttle indication
    TransPyloric Shuttle indication (label)Adults with BMI 35.0–40.0 kg/m² OR BMI 30.0–34.9 kg/m² with one or more obesity‑related comorbid conditions; used with diet and behavior modification
    Approval typePMA (premarket approval) granted April 18, 2019
    DocumentationProviders should document that patients meet FDA‑indicated patient selection criteria when requesting authorization
    Multidisciplinary — definition and context
    Multidisciplinary definitionA bariatric center or regimen combining multiple disciplines (eg, surgeon, obesity medicine specialist, dietitian, behavioral health, exercise specialist) to provide safe, effective care
    Documentation importanceMultidisciplinary evaluation and documentation are expected for surgical and revisional candidates
    Role in coverageMultidisciplinary assessment is referenced repeatedly as part of candidacy and authorization considerations

    Policy Revision History and Material Changes

    2026-08-01material_changeLatest

    Revised list of unproven and not medically necessary procedures: added silastic ring vertical gastric bypass and transoral endoscopic surgery including transoral outlet reduction (TORe); removed stomach aspiration therapy; broadened terminology to group gastrointestinal liners and intragastric balloons under transoral endoscopic surgery and clarified inclusion of endoscopic sleeve gastroplasty (includes OverStitch ™).

    2026-08-01administrative_change

    Updated medical records documentation language clarifying that benefit coverage is determined by federal, state, or contractual requirements; expanded requirements that records fully support medical necessity and be made available upon request.

    2026-08-01coding_update

    Applicable CPT codes updated to reflect annual edits and CPT code 43889 was added to the list of applicable codes.

    2026-08-01supporting_information_update

    Supporting Information sections (Description of Services, Clinical Evidence, FDA, References) were updated to reflect current information and the previous policy version CS007KY.11 was archived.